Abstract
We describe an HIV/HCV coinfected patient with liver cirrhosis, who experienced severe CNS side-effects during efavirenz-based HIV therapy. Plasma levels of efavirenz were 10 times the upper limit and remained elevated (at twice the upper limit) 4 weeks after cessation of therapy. Efavirenz resistance (K103N) developed and was probably due to 'functional' monotherapy.
Publication types
-
Case Reports
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Alkynes
-
Anti-HIV Agents / adverse effects*
-
Anti-HIV Agents / blood*
-
Anti-HIV Agents / therapeutic use
-
Benzoxazines
-
Cyclopropanes
-
Drug Resistance, Viral / genetics
-
Female
-
HIV Infections / complications
-
HIV Infections / drug therapy*
-
HIV-1 / genetics
-
Hepatitis C / complications
-
Humans
-
Liver Cirrhosis / metabolism*
-
Liver Cirrhosis / virology
-
Middle Aged
-
Mood Disorders / chemically induced*
-
Mutation
-
Oxazines / adverse effects*
-
Oxazines / blood*
-
Oxazines / therapeutic use
Substances
-
Alkynes
-
Anti-HIV Agents
-
Benzoxazines
-
Cyclopropanes
-
Oxazines
-
efavirenz